Andrew Rezvani, M.D. | Stanford Medicine

Dr. Andrew Rezvani, MD

Claim this profile

Stanford University

Studies Non-Hodgkin's Lymphoma
Studies Leukemia
7 reported clinical trials
12 drugs studied

Area of expertise

1

Non-Hodgkin's Lymphoma

Andrew Rezvani, MD has run 3 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:

Philadelphia Chromosome positive
CD22 positive
CD22 negative
2

Leukemia

Andrew Rezvani, MD has run 2 trials for Leukemia. Some of their research focus areas include:

CD19 positive
CD22 negative
CD19 negative

Affiliated Hospitals

Image of trial facility.

Stanford University

Image of trial facility.

Stanford Medical Center

Clinical Trials Andrew Rezvani, MD is currently running

More about Andrew Rezvani, MD

Clinical Trial Related

2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Andrew Rezvani, MD has experience with

  • Cyclophosphamide
  • Fludarabine
  • CD22 CAR
  • CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells
  • NKTR-255
  • Fludarabine Phosphate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Andrew Rezvani, MD specialize in?

Is Andrew Rezvani, MD currently recruiting for clinical trials?

Are there any treatments that Andrew Rezvani, MD has studied deeply?

What is the best way to schedule an appointment with Andrew Rezvani, MD?

What is the office address of Andrew Rezvani, MD?

Is there any support for travel costs?